Sweet Earth Holdings Valuation

Is SEHC.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SEHC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SEHC.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SEHC.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SEHC.F?

Key metric: As SEHC.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SEHC.F. This is calculated by dividing SEHC.F's market cap by their current earnings.
What is SEHC.F's PE Ratio?
PE Ratio	3.4x
Earnings	CA$182.92k
Market Cap	CA$620.07k

SEHC.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	67.5x
Enterprise Value/EBITDA	-2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does SEHC.F's PE Ratio compare to its peers?

The above table shows the PE ratio for SEHC.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	6.9x
CNNC Cannonau	0.7x	n/a	US$241.8k
KAYS Kaya Holdings	0.4x	n/a	US$709.5k
EDXC Endexx	0.8x	n/a	US$6.0m
IBO Impact BioMedical	25.8x	n/a	US$30.1m
SEHC.F Sweet Earth Holdings	3.4x	n/a	US$620.1k

Price-To-Earnings vs Peers: SEHC.F is good value based on its Price-To-Earnings Ratio (3.4x) compared to the peer average (7x).

Price to Earnings Ratio vs Industry

How does SEHC.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

9 Companies	Price / Earnings	Estimated Growth	Market Cap
NDOI Endo	0.6x	n/a	US$1.87b
PROC Procaps Group	2x	n/a	US$125.23m
KPRX Kiora Pharmaceuticals	1.8x	-40.4%	US$9.93m
EDXC Endexx	0.8x	n/a	US$5.99m

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: SEHC.F is good value based on its Price-To-Earnings Ratio (3.4x) compared to the US Pharmaceuticals industry average (19.3x).

Price to Earnings Ratio vs Fair Ratio

What is SEHC.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SEHC.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	3.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SEHC.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Kiniksa Pharmaceuticals International

US$1.5b

A biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.

KNSA

US$21.28

-0.05%

33.2%

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$17.12

4.2%

79.3%